OncoSec Announces Changes to its Board of Directors
OncoSec Medical Incorporated (NASDAQ: ONCS) announced significant changes to its Board of Directors. Margaret Dalesandro, Ph.D., has resigned, and Dr. Linda Shi, M.D., Ph.D., has been appointed as the new Chair. Dr. Shi brings over 30 years of experience from various roles, including Chief Medical Officer at Grand Pharma. Additionally, Yuhang Zhao, Ph.D., has also resigned from the Board. The company continues its search for a new CEO, indicating ongoing transitions in leadership.
- Dr. Linda Shi's appointment enhances the leadership team with her extensive experience in clinical and pharmaceutical sectors.
- The ongoing CEO search demonstrates the company's commitment to finding a strong leader for future growth.
- The resignation of key board members may raise concerns about continuity and potential experience gaps in strategic decision-making.
PENNINGTON, N.J. and SAN DIEGO, Dec. 17, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer, today announced that Margaret Dalesandro, Ph.D., Chair of the Board of Directors and member of the Leadership Committee, has resigned from the Board of Directors and the Leadership Committee, effective immediately, and Dr. Linda Shi, M.D., Ph.D., has been added to the OncoSec Board of Directors and appointed Chair.
Kevin Smith remarked, "On behalf of the Board of Directors, we are grateful to Margaret for her leadership, expert guidance, and commitment to the company, particularly over the last six months stepping into her active role on the Leadership Committee. We would like to thank Margaret for her dedication to the company."
Dr. Linda Shi is the deputy president and Chief Medical officer of Grand Pharma (China), as well as an Executive Director of Grand Pharmaceutical Group Limited, a publicly listed company in Hong Kong. Prior to joining Grand Pharma, Dr. Shi was the EU Regulatory Leader in the Global Regulatory Affairs for Neuroscience at Janssen R&D in Belgium. Dr. Shi has over 30 years of clinical and research experience in academic settings and the pharmaceutical industry, with significant experience working with global multifunctional matrixed teams to drive forward complex projects. She led various applications for clinical trials and INDs across Europe and the United States. Dr. Shi obtained her M.D. in China and a Ph.D. in Medical Sciences from Vrije Universiteit Brussel. She has been appointed as a guest professor and visiting fellow in various universities worldwide.
Yuhang Zhao, Ph.D. notified the Company of her resignation as Director and member of the Leadership Committee, effective immediately. Kevin Smith added, "Yuhang made significant contributions to the Board of Directors over the last two years and we are grateful for her efforts."
As a result of the changes, Kevin Smith is now a member of the Leadership Committee.
Lastly, regarding the CEO search, the Leadership Committee and Board of Directors continue to meet with high quality candidates and remain committed to naming a new CEO in the near-term.
About OncoSec Medical Incorporated
OncoSec Medical Incorporated (the "Company," "OncoSec," "we" or "our") is a biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer. OncoSec's lead immunotherapy investigational product candidate – TAVO™ (tavokinogene telseplasmid) – enables the intratumoral delivery of DNA-based interleukin-12 (IL-12), a naturally occurring protein with immune-stimulating functions. The technology, which employs electroporation, is designed to produce a controlled, localized expression of IL-12 in the tumor microenvironment, enabling the immune system to target and attack tumors throughout the body. OncoSec has built a deep and diverse clinical pipeline utilizing TAVO™ as a potential treatment for multiple cancer indications either as a monotherapy or in combination with leading checkpoint inhibitors; with the latter potentially enabling OncoSec to address a great unmet medical need in oncology: anti-PD-1 non-responders. Results from recently completed clinical studies of TAVO™ have demonstrated a local immune response, and subsequently, a systemic effect as either a monotherapy or combination treatment approach along with an acceptable safety profile, warranting further development. In addition to TAVO™, OncoSec is identifying and developing new DNA-encoded therapeutic candidates and tumor indications for use with its new Visceral Lesion Applicator (VLA), to target deep visceral lesions, such as liver, lung or pancreatic lesions. For more information, please visit www.oncosec.com.
TAVO™ is a trademark of OncoSec Medical Incorporated.
Company Contact
Investor Contact
Mike Moyer
LifeSci Advisors
+1-617-308-4306
mmoyer@lifesciadvisors.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/oncosec-announces-changes-to-its-board-of-directors-301447437.html
SOURCE OncoSec Medical Incorporated
FAQ
Who has been appointed as the new Chair of OncoSec's Board of Directors?
What significant changes were announced in OncoSec's Board of Directors?
What is the experience of Dr. Linda Shi in relation to OncoSec?
Is OncoSec currently searching for a new CEO?
